InsuletMIL:1PODD 62 Buyback Yield % is 3.16 as of Jul. 06, 2026. GuruFocus rates MIL:1PODD with a GF Score™ of 62/100 and a GF Value™ of €345.27 (Significantly Undervalued). Among 347 Medical Devices & Instruments companies, Insulet ranks better than 92.22% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Insulet's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1PODD vs GMED, PEN, BRKR: Buyback Yield % Comparison
For the Medical Devices subindustry, Insulet's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insulet Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Insulet's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insulet (MIL:1PODD) has a Buyback Yield % of 3.16 as of Jul. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Insulet and its competitors. According to the industry distribution chart, Insulet ranks #27 out of 347 companies in the Medical Devices & Instruments industry, placing it in the top 7.8%.
Is Insulet's Buyback Yield % too high?
Insulet's current Buyback Yield % is 3.16. Based on the distribution chart, Insulet ranks #27 out of 347 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Insulet has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's Buyback Yield % compare to GMED and PEN?
According to the Medical Devices & Instruments industry distribution chart, Insulet ranks #27 out of 347 companies for Buyback Yield %. This places Insulet in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Insulet and its competitors. Insulet's current Buyback Yield % is 3.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (MIL:1PODD) is currently considered Significantly Undervalued. The stock's GF Value™ is €345.27, compared to a current price of €140.20 — trading 59.4% below its estimated fair value. The current Buyback Yield % is 3.16. Insulet's overall GF Score™ is 62/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Insulet (MIL:1PODD), the current Buyback Yield % is 3.16 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insulet (MIL:1PODD) Overvalued in 2026?
Based on GuruFocus' analysis, Insulet stock appears to be undervalued.
The current stock price of €140.20 is trading 59.4% below its estimated GF Value™ of €345.27.
GuruFocus considers Insulet to be Significantly Undervalued.
Key valuation signals for MIL:1PODD:
Buyback Yield %: 3.16
GF Value™: €345.27 vs. price of €140.20 (59.4% below fair value)
No single metric tells the full story. See the MIL:1PODD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
62GF Score
Get the complete analysis for MIL:1PODD
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1PODD has been successfully added to your 
